Japanese multicenter prospective study investigating laparoscopic surgery for locally advanced rectal cancer with evaluation of CRM and TME quality (PRODUCT trial)

Ichiro Takemasa1 | Atsushi Hamabe1 | Masaaki Ito2 | Shuichiro Matoba3 |
Jun Watanabe4 | Suguru Hasegawa5 | Masanori Kotake6 | Masafumi Inomata7 |
Kazuki Ueda8 | Kay Uehara9 | Kazuhiro Sakamoto10 | Masataka Ikeda11 |
Tsunekazu Hanai12 | Tsuyoshi Konishi13 | Shigeki Yamaguchi14 | Daisuke Nakano15 |
Shigeru Yamagishi16 | Kenji Okita1 | Atsushi Ochiai17 | Yoshiharu Sakai18 |
Masahiko Watanabe19 | on behalf of Japan Society of Laparoscopic Colorectal Surgery

1Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Japan
2Department of Colorectal Surgery, National Cancer Center Hospital East, Kashiwa, Japan
3Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan
4Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
5Department of Gastroenterological Surgery, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
6Department of Surgery, Koseiren Takaoka Hospital, Toyama, Japan
7Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Yufu, Japan
8Department of Surgery, Kindai University Faculty of Medicine, Osaka, Japan
9Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
10Department of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan
11Division of Lower Gastrointestinal Surgery, Department of Gastroenterological Surgery, Hyogo College of Medicine, Nishinomiya, Japan
12Department of Surgery, Fujita Health University, School of Medicine, Toyoake, Japan
13Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan
14Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, Japan
15Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
16Department of Surgery, Fujisawa Municipal Hospital, Fujisawa, Japan
17Division of Biomarker Discovery, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Japan
18Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
19Department of Surgery, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

Correspondence
Ichiro Takemasa, Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Japan, S1 W16, Chuo-ku, Sapporo 060-8543, Japan. Email: itakemasa@sapmed.ac.jp

Abstract
Aim: In Japan, we have not been able to validate the results of laparoscopic surgery for locally advanced rectal cancer using the universal index "circumferential resection margin (CRM)." Previously, we established a semi-opened circular specimen processing method and validated its feasibility. In the PRODUCT trial, we aimed to assess...
INTRODUCTION

Rectal resection still remains the mainstay in multidisciplinary treatment for locally advanced rectal cancer (LARC), and the quality of surgery is directly associated with postoperative local recurrence.1–3 Although the local recurrence rate for Dukes stage C was as high as 40% two decades ago, the establishment of total mesorectal excision (TME) since 1982 and adoption of neoadjuvant chemoradiotherapy as standard treatment have decreased the rate to approximately 5%.4–6 Different from Western countries, however, Japanese surgeons have adopted a unique strategy for LARC in which rectal resection with lateral lymph node dissection (LLND) is performed first regardless of preoperative staging, followed by postoperative chemotherapy.1 Despite this discrepancy, the long-term results are comparable between Japan and Western countries.7

Although the treatment strategies evolved individually in Japan and in Western countries, the addition of LLND after neoadjuvant CRT can further prevent recurrence at the lateral pelvic cavity for patients with swollen nodes at baseline.8 This indicates that not all metastasized lateral lymph nodes can be eradicated with CRT alone, urging Western surgeons to indicate LLND for high-risk patients.9 Japanese surgeons started to use neoadjuvant CRT to prevent local recurrence that cannot be prevented by LLND. The optimization of combination treatment with neoadjuvant CRT and LLND would be a key factor in completely preventing local recurrence after surgery for LARC.9

The indication for the combination of neoadjuvant CRT and/or LLND has to be discussed on the premise that the quality of rectal resection is appropriately ensured. However, the quality of Japanese surgery cannot have been evaluated in a pathological manner that is comparable to the method used in Western countries. According to the Japanese guidelines, the mesorectum is dissected off completely to harvest the perirectal lymph nodes and the rectum longitudinally opened to assess the macroscopic features of the tumor, which have long been emphasized for the evaluation of malignant potential,10,11 leaving an inappropriate specimen for measuring the circumferential resection margin (CRM). Due to these differences, we have not been able to measure CRM in Japanese practice, and the results of LARC treatment including LLND in Japan have not been accurately interpreted in Western countries. To resolve the inability to measure CRM in Japanese practice, we established a semi-opened circular specimen processing method and validated its feasibility12,13 to successfully measure pathological CRM. Based on this background, we aimed to prospectively assess the quality of laparoscopic surgery for LARC in Japan in a multicenter study by assessing the universal standard, CRM.

METHODS

2.1 Study design

This was a multicenter, prospective, observational study conducted in Japan. A total of 18 institutions from the Japan Society of Laparoscopic Colorectal Surgery participated in the study. Eligible patients were ≥20 years old, had histologically confirmed rectal

CRM in patients with locally advanced rectal cancer who underwent laparoscopic rectal resection.

Methods: This was a multicenter, prospective, observational study. Eligible patients had histologically confirmed rectal adenocarcinoma located at or below 12 cm above the anal verge with clinical stage II or III and were scheduled for laparoscopic or robotic surgery. The primary endpoint was pathological CRM. CRM ≤1 mm was defined as positive.

Results: A total of 303 patients operated on between August 2018 and January 2020 were included in the primary analysis. The number of patients with clinical stage II and III was 139 and 164, respectively. Upfront surgery was performed for 213 patients and neoadjuvant therapy for 90 patients. The median CRM was 4.0 mm (IQR, 2.1-8.0 mm), and CRM was positive in 26 cases (8.6%). Univariate and multivariate analyses demonstrated that a predicted CRM from the mesorectal fascia of ≤1 mm on MRI was the significant factor for positive CRM (P = .0012 and P = .0045, respectively).

Conclusion: This study showed the quality of laparoscopic rectal resection based on the CRM in Japan. Preoperative MRI is recommended for locally advanced rectal cancer to prevent CRM positivity.

Keywords: laparoscopy, magnetic resonance imaging, margins of excision, rectal neoplasms, total mesorectal excision
adenocarcinoma located ≤12 cm above the anal verge with clinical stage II or III (T2N0MO, T1-4aN1-2M0), and scheduled for laparoscopic or robotic surgery. The deepest part of the tumor could be diagnosed as T4a, a tumor extending above the peritoneal reflection, and be regarded as eligible on the condition that the adjacent organ was not invaded. Rectal magnetic resonance imaging (MRI) was used for the assessment of T and N staging, and the clinical stage was assessed based on the images before neoadjuvant therapy. The indication for neoadjuvant therapy, surgical approaches, or LLND were at the discretion of each hospital. Exclusion criteria were as follows: a history of active double cancer (synchronous cancer, or metachronous cancer with disease-free interval <5 years), cancer invading the adjacent organs, or psychiatric or addictive disorders that affected compliance with the protocol. The target sample size was 300, considering that previous randomized controlled trials comparing laparoscopic surgery to open surgery included approximately 200 patients for laparoscopic surgery,\textsuperscript{14-16} and that the estimated patients were 300 per year in participating institutions. All operations were controlled by credentialed surgeons in possession of an endoscopic surgical skill qualification system: qualified surgeon granted by the Japan Society for Endoscopic Surgery. The surgical approach could include not only conventional laparoscopic surgery (CLS) but also robotic-assisted laparoscopic surgery (RALS). The study protocol was approved by the institutional review boards of the individual participating institutions. Written informed consent was obtained from all patients. This study was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry, Identification Number: UMIN00034364 (http://www.umin.ac.jp/ctr/index.htm).

2.2 | Outcomes

The primary outcome was a pathological CRM measured using the semi-opened circular specimen processing method. CRM was defined as negative if the distance between the closest tumor invasion and dissected plane was more than 1 mm. The secondary outcomes included the quality of TME, surgical and pathological findings, disease-free survival, overall survival, and local recurrence rate. Our original plan was to report short-term results, including CRM, which is the primary endpoint of this study, and then demonstrate long-term results after completing a follow-up of all patients according to the previous randomized controlled trials, including ALACaRT or Z6051.\textsuperscript{5,6} The quality of the mesorectal excision was categorized as complete, nearly complete, or incomplete according to the Dutch TME trial: complete, smooth surface of mesorectal fascia with all fat contained in the enveloping fascia; nearly complete, the mesorectal envelope was intact except for defects no more than 5 mm deep, with no loss of mesorectal fat; incomplete, low bulk mesorectum with defects down onto the muscularis propria and/or a very irregular circumferential resection margin.\textsuperscript{17} The site of the lower border of the primary tumor (upper or lower) was categorized according to the subclassification of the 12 cm of rectum into equal halves. In assessing the clinical and pathological stage, the lateral lymph node was regarded as regional nodes according to the Japanese guidelines, and tumors with isolated metastasis to lateral lymph nodes were categorized as stage III.

2.3 | Pathological assessment

The resected specimen was photographed from four directions to confirm the quality of the dissected mesorectal fascia: anteriorly, from right, from left, and posteriorly. The procedure for semi-opened circular specimen processing was described in detail in our previous reports.\textsuperscript{12} Briefly, the area of the rectum between 2 cm above and below the borders of the rectal cancer is not incised and the corresponding mesorectum is left attached to the rectum in order to measure the CRM. In assessing the CRM, if the tumor invasion in lymph node metastasis, extramural vascular invasion (EMVI), or tumor deposit is closer to the dissected plane than the main tumor invasion, the closer distance is recorded as the CRM. The feasibility of this procedure for pathological assessment was previously verified in a multicenter, prospective, observational study, thereby confirming that the quality of semi-opened circular specimen processing could be maintained in our study group.\textsuperscript{13}

2.4 | Statistical analysis

Statistical analyses were performed using JMP pro 15.1.0 software (SAS Institute, Cary, NC, USA). The results are expressed as the number of cases evaluated for categorical data, or as the median and interquartile range (IQR) for quantitative data. Univariate analyses were performed using Fisher’s exact test or the Mann-Whitney U test as appropriate. Factors associated with CRM positivity were assessed using a multivariate logistic regression model. $p<0.05$ was considered to be statistically significant.

3 | RESULTS

3.1 | Patient background and tumor characteristics

Between August 2018 and January 2020, a total of 308 patients were enrolled in this study (Figure 1). Five patients were excluded after enrollment: two patients were ineligible because the tumor invaded the adjacent organs at baseline diagnosis, one patient withdrew consent, and two patients were ineligible for other reasons. Finally, 303 patients (202 males and 101 females) were included in the primary analysis.

Table 1 shows the patient and tumor characteristics. The median patient age was 66 years. At baseline, 139 cases were stage II and 164 stage III. Metastasis to lateral lymph nodes was suspected in 30 cases. The median distance from the lower border of the tumor to the anal verge was 70 mm (IQR, 40-120 mm). Regarding
neoadjuvant therapy, 213 patients received upfront surgery, and the other 90 patients underwent neoadjuvant therapy, including 27 cases of CRT, 45 cases of neoadjuvant chemotherapy (NAC), and 18 cases of total neoadjuvant therapy. No metastasis to distant organs was found after neoadjuvant therapy, and rectal resection could be performed for all cases undergoing neoadjuvant therapy.

### 3.2 Surgical outcomes

Table 2 summarizes the results of the surgeries. CLS was performed for 167 cases and RALS for 136 cases. Regarding operative procedures, anterior resection was carried out for 240 cases, intersphincteric resection for 40 cases, abdominoperineal excision for 19 cases, and the Hartmann’s operation for four cases. The transanal approach was utilized in 78 cases, and the distance from the anal verge was significantly shorter in these patients than those in whom the transanal approach was not used (median [IQR], 60 [40-70] mm vs 70 [50-100] mm, P < .0001). A diverting stoma was created for 177 cases.

The median operative duration was 336 minutes and blood loss 12 mL, whereas the operative duration was 320 minutes and blood loss 7 mL if excluding the cases in which LLND was performed. Regarding postoperative complications (Clavien-Dindo ≥III), anastomotic leakage was found in 22 cases (rate of leakage, 7.3%), surgical site infection other than leakage in 10 cases, bowel obstruction in eight cases, paralytic ileus in 10 cases, and other complications in 30 cases. The median hospital stay was 14 days (12-21 days).

### 3.3 Pathological outcomes

Pathological outcomes are shown in Table 3. The median length of pathologically assessed CRM, the primary endpoint of this study, was 4.0 mm (IQR, 2.1-8.0 mm), and CRM was ≤1 mm in 26 cases, corresponding to a positivity rate of 8.6%. In these 26 cases, the CRM was positive at the site of the main tumor in 18 cases and positive at metastasized lymph nodes in six cases, a tumor nodule in one case, and at the intra-lymphatic duct invasion in one case. Of the eight cases in which CRM was positive at a site other than the main tumor, there were no cases in which CRM status could be diagnosed correctly based on MRI. Regarding pathological staging, pCR was confirmed in 14 cases, and two, 76, 104, and 107 cases were stage 0, I, II, and III, respectively. The pCR rate corresponded to 15.6%. Metastasis to lateral lymph nodes was confirmed in 12 cases, including three cases with isolated metastasis to lateral lymph nodes. In evaluation of the TME quality, 293 cases were complete and 10 nearly complete. The distal resection margin (DRM) was positive in one case.

#### 3.4 Analysis of the risk factors for positive CRM

Table 4 summarizes the results of univariate analyses for the association between CRM positivity and the preoperative and operative variables. The predicted CRM from the mesorectal fascia being ≤1 mm on baseline MRI was found to be a significant risk factor for pathologically positive CRM (P = .0012). Among the 90 cases with neoadjuvant therapy, 84 underwent a second MRI to assess the therapeutic effect. The predicted CRM was positive on MRI in seven cases, four of which were diagnosed as pathologically positive. In contrast, among 77 cases with a negative predicted CRM on MRI, six were pathologically positive, which was significantly lower than the number predicted CRM to be positive (P = .0001). Although predicted CRM on MRI was suggested to be a risk factor after neoadjuvant therapy, we used the baseline MRI findings as candidate factors in the subsequent analysis because it was difficult to universally diagnose MRI after neoadjuvant therapy, which can be affected by therapeutic modifications. The multivariate analysis was carried out using the independent factors, including the predicted CRM from the mesorectal fascia on MRI and tumor stage ≥T4a, as well as tumor site and distance from the anal verge, which are the established risk factors for CRM positivity in the MERCURY II study. The cut-off value for the distance from the anal verge was defined as 60 mm, considering the fact that low rectal cancer located ≤6 cm from the anal verge was regarded as a definite risk factor for CRM positivity in rectal cancer. As shown in Table 5, a predicted CRM from the mesorectal fascia ≤1 mm on baseline MRI was demonstrated to be a significant factor, but the other factors were not shown to be related to the CRM positivity.

### 4 DISCUSSION

In this study, we assessed the pathological CRM for LARC operated on patients in Japan in a multicenter prospective study using the semi-opened circular specimen processing method. Until now, we have not been able to validate the oncological results of rectal cancer treatment in Japan by directly comparing it to the results in
### TABLE 1  Patient and tumor characteristics

#### Patient characteristics (N = 303)

| Characteristic                   | Value          |
|----------------------------------|----------------|
| Age, years                       | 66 (56-74)     |
| Male sex                         | 202 (66.7)     |
| BMI, kg/m²                       | 22.0 (20.2-24.1) |
| ASA-PS                           |                |
| 0-1                              | 288 (95.0)     |
| 2                                | 15 (5.0)       |

#### Tumor characteristics at initial examination (N = 303)

| Characteristic                   | Value          |
|----------------------------------|----------------|
| Distance from the anal verge, mm | 70 (45-100)    |
| Location of the center of the tumor |                |
| Anterior                         | 85 (28.1)      |
| Posterior                        | 74 (24.4)      |
| Right                            | 31 (10.2)      |
| Left                             | 64 (21.1)      |
| Circular                         | 49 (16.1)      |
| Tumor stage at baseline          |                |
| cT1                              | 1 (0.3)        |
| cT2                              | 11 (3.6)       |
| cT3                              | 262 (86.5)     |
| cT4a                             | 29 (9.6)       |
| Nodal status at baseline         |                |
| cN0                              | 139 (45.9)     |
| cN1                              | 129 (42.6)     |
| cN2                              | 35 (11.6)      |
| Suspected metastasis to lateral lymph node | 30 (9.9) |
| Clinical stage at baseline       |                |
| Stage II                         | 139 (45.9)     |
| Stage III                        | 164 (54.1)     |
| Neoadjuvant therapy              |                |
| None                             | 213 (70.3)     |
| (C)RT                            | 27 (8.9)       |
| NAC                              | 45 (14.9)      |
| TNT                              | 18 (5.9)       |

#### Tumor characteristics after neoadjuvant therapy (N = 90)

| Characteristic                   | Value          |
|----------------------------------|----------------|
| Tumor stage after neoadjuvant therapy |          |
| ycT0                             | 1 (1.1)        |
| ycT1                             | 3 (3.3)        |
| ycT2                             | 18 (20.0)      |
| ycT3                             | 60 (66.7)      |
| ycT4a                            | 5 (5.6)        |
| Not assessed                     | 3 (3.3)        |
| Nodal status after neoadjuvant therapy |           |
| ycN0                             | 58 (64.4)      |
| ycN1                             | 23 (25.6)      |
| ycN2                             | 6 (6.7)        |

(Continues)
Western countries due to the lack of CRM data, which is a definitive predictive marker of future relapse. This restriction has been a hindrance for a number of past Japanese clinical studies to be appraised internationally, which needed to be solved by defining the tumor characteristics using CRM. Therefore, this study is important, as using the semi-opened circular specimen processing method to assess CRM could demonstrate the results of laparoscopic surgery for LARC in Japan, where a different strategy has been adopted compared to Western countries, and also show the rate of positive CRM in Japan, which can be used as a reference in future trials. This method is beneficial in that we can easily harvest the tumor sample from the resected specimen, which would be mandatory in the era of genome medicine.

There have been four randomized controlled trials comparing the results of laparoscopic surgeries for LARC to the results of open surgeries. Although the COREAN trial\textsuperscript{15} and COLOR II trial\textsuperscript{20} showed favorable results of laparoscopic surgery, the ALaCaRT trial and Z6051 trial could not demonstrate the non-inferiority of laparoscopic surgery to open surgery by validating the successful resection rate based on several factors, including the assessment of CRM positivity, raising concerns about the application of laparoscopic surgery to LARC\textsuperscript{14,16}. In analyses of the long-term results of the above two trials, laparoscopic surgery was eventually demonstrated not to be a risk factor for disease-free survival, though pathological CRM was the single, poor prognostic factor\textsuperscript{5,6}. These data suggested that, in the era of multimodal therapy for locally advanced rectal cancers, obtaining a CRM of more than 1 mm is the most crucial factor to achieving sufficient curability regardless of the surgical approach. In this regard, assessment of CRM is essential to validate the surgical quality and predict patient prognosis. The CRM in this study was shown to be 8.6%, and approximately 70% of the cases were positive at the site of the main tumor. Intriguingly, one-third of the patients were positive at a site other than the main tumor, suggesting the importance of preoperative assessment in tumor expansion in the mesorectum. The positivity rate of CRM was lower in the COREAN (2.1%) and ALaCaRT (6.7%) trials, and higher in the COLOR II (9.5%) and Z6051 (12.1%) trials, compared to the rate in the PRODUCT trial.

In interpreting the differences in CRM positivity, the differences in the enrolled patients should be considered. In contrast to the other trials, neoadjuvant therapy was administered in as few as 30% of cases in the presented study, and NAC was used in roughly half of the patients. Furthermore, more advanced cases were enrolled in this study based on the pathological tumor stage, and more than

| TABLE 1 (Continued) |
|----------------------|
| **Tumor characteristics after neoadjuvant therapy (N = 90)** |
| Not assessed | 3 (3.3) |
| Suspected metastasis to lateral lymph node | 17 (18.9) |
| cCR | 1 (1.1) |

Note: Values are given as median (IQR) or n (%).
Abbreviations: ASA-PS, American Society of Anesthesiologists physical status; BMI, body mass index; CR, complete response; CRT, chemoradiotherapy; IQR, interquartile range; NAC, neoadjuvant chemotherapy; RT, radiotherapy; TNT, total neoadjuvant therapy.

| TABLE 2 Operative results |
|---------------------------|
| **Approach** |
| CLS | 167 (55.1) |
| RALS | 136 (44.9) |
| TaTME performed | 78 (25.7) |
| **Procedure** |
| LAR | 240 (79.2) |
| ISR | 40 (13.2) |
| APR | 19 (6.3) |
| Hartmann | 4 (1.3) |
| **LLND** |
| None | 213 (70.3) |
| Bilateral | 76 (25.1) |
| Unilateral | 14 (4.6) |
| **Diverting stoma created** | 177 (62.1) |
| **Operative duration, min** | 336 (256-470) |
| **Operative duration excluding LLND cases, min** | 320 (256-393) |
| **Blood loss, mL** | 12 (5-50) |
| **Blood loss excluding LLND cases, mL** | 7 (1-50) |
| **Open conversion** | 1 (0.3) |
| **30-day mortality** | 0 (0.0) |
| **Length of hospital stay, days** | 14 (12-21) |
| **Grade 3-4 postoperative complications** |
| Leakage | 22 (7.3) |
| Bowel obstruction | 8 (2.6) |
| Ileus | 10 (3.3) |
| SSI (excluding leak) | 10 (3.3) |
| Urological complication | 10 (3.3) |
| Cardiovascular complication | 4 (1.3) |
| Respiratory complication | 3 (1.0) |
| Hemorrhage | 3 (1.0) |
| Others | 10 (3.3) |

Note: Values are given as median (IQR) or n (%).
Abbreviations: APR, abdominoperineal resection; CLS, conventional laparoscopic surgery; IQR, interquartile range; ISR, intersphincteric resection; LAR, low anterior resection; LLND, lateral lymph node dissection; RALS, robotic-assisted laparoscopic surgery; SSI, surgical site infection; TaTME, transanal total mesorectal excision.
50% of the cases had T3-T4. The definition of CRM positivity also differed. CRM is defined as positive if ≤2 mm in the COLOR II trial, <1 mm in the ALaCaRT trial, or ≤1 mm in the COREAN and Z6051 trial and this study. The positive CRM rate of 8.6% in this study should be considered by taking the above-mentioned differences into account. There could be room to further improve the positive rate and some measures need to be taken, including the application of multimodal therapy for high-risk patients. Based on the sufficient treatment for local control, the indication of the intensified treatment to prevent distant metastasis, such as total neoadjuvant therapy, should be discussed.

This study has shown that the tumor proximity to the mesorectal fascia assessed on baseline MRI is an independent risk factor for positive CRM. In the current Japanese guidelines, we cannot see any recommendation for implementing MRI as a preoperative work-up in the treatment of rectal cancer, which is a mandatory exam in

| Outcomes | All cases (N = 303) | | Neoadjuvant therapy |
|----------|---------------------|---------------------|
| CRM, mm  | 4.0 (2.1-8.0)       | 4.0 (2.2-8.0)       | 4.2 (2.1-8.0) |
| With negative margin (>1 mm) | 277 (91.4) | 197 (92.5) | 80 (88.9) |
| With positive margin (≤1 mm) | 26 (8.6) | 16 (7.5) | 10 (11.1) |
| Tumoral region with CRM-positivity (N = 26) | | |
| Main tumor | 18 (69.2) | 9 (56.3) | 9 (90.0) |
| Lymph node | 6 (23.1) | 5 (31.3) | 1 (10.0) |
| Tumor nodule without residual lymph node structure | 1 (3.8) | 1 (6.3) | 0 (0) |
| Intra-lymphatic duct invasion | 1 (3.8) | 1 (6.3) | 0 (0) |
| Total mesorectal excision | | |
| Complete | 293 (96.7) | 205 (96.2) | 88 (97.8) |
| Nearly complete | 10 (3.3) | 8 (3.8) | 2 (2.2) |
| Incomplete | 0 (0.0) | 0 (0) | 0 (0) |
| Tumor size, mm | 36 (30-45) | 35 (30-45) | 38 (30-45) |
| Pathological tumor stage | | |
| pT0 | 16 (5.3) | 0 (0) | 16 (17.8) |
| pTis | 2 (0.7) | 0 (0) | 2 (2.3) |
| pT1 | 10 (3.3) | 6 (2.8) | 4 (4.7) |
| pT2 | 84 (28.1) | 59 (27.7) | 25 (29.1) |
| pT3 | 176 (58.9) | 139 (65.3) | 37 (43.0) |
| pT4a | 14 (4.7) | 9 (4.2) | 5 (5.8) |
| pT4b | 1 (0.3) | 0 (0) | 1 (1.2) |
| Pathological nodal stage | | |
| pN0 | 196 (64.7) | 134 (62.9) | 62 (72.2) |
| pN1 | 74 (24.4) | 51 (23.9) | 23 (22.2) |
| pN2 | 33 (10.9) | 28 (13.1) | 5 (5.6) |
| Metastasis to lateral lymph node | | |
| Pathological stage | | |
| pCR | 14 (4.6) | - | 14 (15.6) |
| Stage 0 | 2 (0.7) | 0 (0) | 2 (2.2) |
| Stage I | 76 (25.1) | 50 (23.5) | 26 (28.9) |
| Stage II | 104 (34.3) | 84 (39.4) | 20 (22.2) |
| Stage III | 107 (35.3) | 79 (37.1) | 28 (31.1) |
| PRM, mm | 120 (100-150) | 120 (100-150) | 130 (105-163) |
| DRM, mm | 20 (15-30) | 25 (15-31) | 20 (12-30) |

Note: Values are given as median (IQR) or n (%).
Abbreviations: CR, complete response; CRM, circumferential resection margin; DRM, distal resection margin; IQR, interquartile range; PRM, proximal resection margin.
### TABLE 4  Univariate analyses of the risk factors for positive CRM

|                      | CRM-negative (N = 277) | CRM-positive (N = 26) | P-value |
|----------------------|------------------------|-----------------------|---------|
| **Patient characteristics** |                        |                       |         |
| Median age (IQR), years | 66 (56-74)             | 67 (53-76)            | .7895   |
| Sex, n (%)            |                        |                       | .1907   |
| Male                  | 188 (67.9)             | 14 (53.8)             |         |
| Female                | 89 (32.1)              | 12 (46.2)             |         |
| Median BMI (IQR), kg/m² | 22.0 (20.4-24.1)       | 20.7 (19.5-23.7)      | .1906   |
| **Tumor characteristics at initial examination** |                        |                       | .0876 (T1-3 vs T4a) |
| Tumor stage, n (%)    |                        |                       |         |
| cT1                   | 1 (0.4)                | 0 (0.0)               |         |
| cT2                   | 11 (4.0)               | 0 (0.0)               |         |
| cT3                   | 241 (87.0)             | 21 (80.8)             |         |
| cT4a                  | 24 (8.7)               | 5 (19.2)              |         |
| Nodal status, n (%)   |                        |                       | .8375 (N0 vs N1-2) |
| cN0                   | 128 (46.2)             | 11 (42.3)             |         |
| cN1                   | 117 (42.2)             | 12 (46.2)             |         |
| cN2                   | 32 (11.6)              | 3 (11.5)              |         |
| Distance from the anal verge |                       |                       | .1536   |
| >60 mm                | 149 (53.8)             | 10 (38.5)             |         |
| ≤60 mm                | 128 (46.2)             | 16 (61.5)             |         |
| Neoadjuvant therapy   |                        |                       | .3691   |
| Yes                   | 80 (28.9)              | 10 (38.5)             |         |
| No                    | 197 (71.1)             | 16 (61.5)             |         |
| Predicted CRM from mesorectal fascia on MRI |                   |                       | .0012* |
| >1 mm                 | 245 (92.1)             | 17 (68.0)             |         |
| ≤1 mm                 | 21 (7.9)               | 8 (32.0)              |         |
| Tumor site            |                        |                       | .5421   |
| Anterior              | 121 (43.7)             | 13 (50.0)             |         |
| Not anterior          | 156 (56.3)             | 13 (50.0)             |         |
| **Surgery**           |                        |                       |         |
| TaTME                 |                        |                       |         |
| Yes                   | 74 (26.7)              | 4 (15.4)              | .2479   |
| No                    | 203 (73.3)             | 22 (84.6)             |         |
| Approach              |                        |                       |         |
| Laparoscopy           | 154 (55.6)             | 13 (50.0)             | .6812   |
| Robot                 | 123 (44.4)             | 13 (50.0)             |         |
| Procedure             |                        |                       | 0.5995  |
| LAR                   | 221 (79.8)             | 19 (73.1)             |         |
| ISR                   | 36 (13.0)              | 4 (15.4)              |         |
| APR                   | 16 (5.8)               | 3 (11.5)              |         |
| Hartmann              | 4 (1.4)                | 0 (0.0)               |         |

Note: Values are given as median (IQR) or n (%). MRI was not performed in 13 cases.

Abbreviations: APR, abdominoperineal resection; BMI, body mass index; CRM, circumferential resection margin; IQR, interquartile range; ISR, intersphincteric resection; LAR, low anterior resection; TaTME, transanal total mesorectal excision. * indicates statistically significant.
Western countries. In Japan, upfront surgery has been a mainstay for advanced rectal cancer regardless of the individual tumor status; thus, the importance of finding various malignant features to assess on MRI has long been undervalued. However, given that the tumor proximity to the mesorectal fascia on MRI has been demonstrated to be a definitive risk factor for positive CRM in the setting of tertiary referral hospitals in Japan, we argue that baseline MRI assessment should be carried out for LARC similar to in Western countries. The number of MRIs installed in Japan is quite high, though the protocol or procedure for acquiring high-resolution images for LARC is not standardized. Thus, the surgical plane to be dissected or the indication for neoadjuvant therapy should be evaluated preoperatively based on MRI findings. In the ESMO guidelines, EMVI, a well-known risk factor for distant metastasis or positive CRM, has to be assessed preoperatively to decide on the multimodal therapy. However, we did not evaluate EMVI in this study because the assessment for EMVI is not currently general in Japan. We consider that mrEMVI should be validated in a future sub-analysis using these datasets after achieving consensus on diagnosis using MRI with expert radiologists, and that the basis for interpreting EMVI on MRI should be constructed. Moreover, considering the fact that CRM was positive at a site other than the main tumor in one-third of cases, it would be ideal if the accuracy of MRI for diagnosing the tumor extension beyond the main tumor is improved even though it is a challenging task.

Various types of surgery were utilized in the analyzed cases. Today, we can adopt several approaches other than CLS in the field of minimally invasive surgery, including the advancement and spread of RALS and transanal TME. Both approaches aim to improve the quality of TME and secure the achievement of negative CRM. This study showed equivalent results for several approaches, including CLS. The ROLARR trial could not show the superiority of RALS compared to CLS in regards to the rate of open conversion as a primary endpoint, as well as CRM. However, in the ROLARR trial, the strict regulation was not set up for an operator of RALS, which was considered a possible factor affecting the results. In the PRODUCT study, not a few RALS were performed by surgeons on the learning curve. To validate the efficiency of RALS for LARC, we are now conducting a multicenter prospective observational study to analyze CRM as a primary endpoint (VITRUVIANO trial, UMIN000039685) in which the surgeons have to be credentialled based on the number of performed cases not being less than 40. With regard to transanal TME, this procedure is considered beneficial in securely obtaining a free DRM, as well as CRM for the tumor close to the anal verge. Despite significance not being found, the distance from the anal verge was shorter in cases with a transanal approach, suggesting that it may offer a chance to prevent CRM positivity in such cases.

The present study has several limitations. First, the single-arm cases cannot be compared to the results of open surgery. Second, the long-term results were not analyzed in this study; therefore, we cannot conclude that the Japanese laparoscopic surgeries are feasible for LARC. Validation of the long-term results of the included patients is going to be carried out in a future ancillary analysis.

In conclusion, this study has demonstrated the results of Japanese CRM after laparoscopic rectal resection for LARC for the first time. CRM positivity was found in 8.6% of cases, one-third of which were positive at a site other than the main tumor. MRI should be carried out for patients with possible LARC at baseline to decide on the surgical plane. The rate of positive CRM shown in this study will play an important role as a reference value in future studies.

ACKNOWLEDGEMENT

The following doctors cooperated in this study: Hasegawa Tadashi (Department of Clinical Pathology, Sapporo Medical University), Motohiro Kojima (Pathology Division, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center), Tsutomu Daa (Department of Diagnostic Pathology, Faculty of Medicine, Oita University), Hiroshi Kawachi (Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research), Takaki Sakurai (Department of Diagnostic Pathology, Kyoto University Graduate School of Medicine), Tsutomu Yoshida (Department of Pathology, Kitasato University School of Medicine).

DISCLOSURE

Funding: This study received no funding.

Conflicts of Interest: Tsuyoshi Konishi reported lecture fees from Johnson & Johnson Japan and Medtronic Japan. The other authors declare no conflicts of interest. Ichiro Takemasa, Jun Watanabe, Masafumi Inomata, and Kay Uehara are editorial members of Annals of Gastroenterological Surgery.

Author contributions: Conceptualization: Ichiro Takemasa, Yoshiharu Sakai, Masahiko Watanabe; Methodology, patient enrollment, formal analysis and investigation: Ichiro Takemasa, Atsushi Hamabe, Masaaki Ito, Shuichiro Matoba, Jun Watanabe, Suguru Hasegawa.
Masanori Kotake, Masafumi Inomata, Kazuki Ueda, Kay Uehara, Kazuhiro Sakamoto, Masataka Ikeda, Tsunekazu Hanai, Tsuyoshi Konishi, Shigeki Yamaguchi, Daisuke Nakano, Shigeru Yamagishi, Kenji Okita, Atsushi Ochiai, Yoshiharu Sakai, Masahiko Watanabe; Principal investigators in participating hospitals of this multicenter study: Ichiro Takemasa, Masaaki Ito, Shuichiro Matoba, Jun Watanabe, Suguru Hasegawa, Masanori Kotake, Masafumi Inomata, Kazuki Ueda, Kay Uehara, Kazuhiro Sakamoto, Masataka Ikeda, Tsunekazu Hanai, Tsuyoshi Konishi, Shigeki Yamaguchi, Daisuke Nakano, Shigeru Yamagishi, Yoshiharu Sakai, Masahiko Watanabe; Writing - original draft preparation: Atsushi Hamabe, Kenji Okita; Writing - review and editing: Ichiro Takemasa, Yoshiharu Sakai, Masahiko Watanabe.

Compliance and Ethical Standards: The protocol for this study was approved by the institutional review boards of the participating hospitals. Written informed consent was obtained from all patients.

Japanese multicenter prospective study investigating laparoscopic surgery for locally advanced rectal cancer with evaluation of CRM and TME quality (PRODUCT trial) was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry, Identification Number: UMIN00034364 (http://www.umin.ac.jp/ctr/index.htm).

REFERENCES
1. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the colon and Rectum (JSSCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42.
2. Glynne-Jones R, Wyrwicz L, Tirtet E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:i22–40.
3. National Comprehensive Cancer Network. Rectal cancer (Version 2.2021). 2021.
4. Swedish Rectal Cancer T, Cedermark B, Dahlberg M, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980–7.
5. Fleshman J, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, et al. Disease-free survival and local recurrence for laparoscopic resection compared with open resection of stage II to III Rectal Cancer: follow-up results of the ACOSOG Z6051 randomized controlled trial. Ann Surg. 2019;269:589–95.
6. Stevenson ARL, Solomon MJ, Brown CSB, Lumley JW, Hewett P, Clouston AD, et al. Disease-free survival and local recurrence after laparoscopic-assisted resection or open resection for Rectal Cancer: the Australasian laparoscopic Cancer of the rectum randomized clinical trial. Ann Surg. 2019;269:596–602.
7. Kusters M, Beets GL, van de Velde CJ, et al. A comparison between the treatment of low rectal cancer in Japan and The Netherlands, focusing on the patterns of local recurrence. Ann Surg. 2009;249:229–35.
8. Ogura A, Konishi T, Cunningham C, Garcia-Aguilar J, Iversen H, Toda S, et al. Neoadjuvant (chemo)radiotherapy with Total Mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 Rectal Cancer. J Clin Oncol. 2019;37:33–43.
9. Takemasa I. Advances and controversies in treatment for locally advanced rectal cancer over the past decades: West meets east. Ann Gastroenterol Surg. 2020;4:314–5.
10. Inomata M, Ochiai A, Sugihara K, Moriya Y, Yamaguchi N, Adachi Y, et al. Macroscopic features at the deepest site of tumor penetration predicting liver metastases of colorectal cancer. Jpn J Clin Oncol. 1998;28:123–8.
11. Watanabe T, Muto T. Colorectal carcinogenesis based on molecular biology of early colorectal cancer, with special reference to nonpolyoid (superficial) lesions. World J Surg. 2000;24:1091–7.
12. Ishii M, Takemasa I, Okita K, Okuya K, Hamabe A, Nishidate T, et al. A modified method for resected specimen processing in rectal cancer: semi-opened with transverse slicing for measuring of the circumferential resection margin. Asian J Endosc Surg. 2021;15:437–42.
13. Takemasa I, Okuya K, Okita K, Ishii M, Ito M, Uehara K, et al. Feasibility of the semi-opened method of specimen resection for a circumferential resection margin in rectal cancer surgery: a multicenter study. Surg Today. 2022. Online ahead of print.
14. Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, et al. Effect of laparoscopic-assisted resection vs open resection of stage II or III Rectal Cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA. 2015;314:1346–55.
15. Jeong S-Y, Park JW, Nam BH, Kim S, Kang SB, Lim SB, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15:767–74.
16. Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, et al. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. JAMA. 2015;314:1356–63.
17. Nagtegaal ID, van de Velde CJ, van der Worp E, et al. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20:1729–34.
18. Chand M, Evans J, Swift Rl, Tekkis PP, West NP, Stamp G, et al. The prognostic significance of postchemoradiotherapy high-resolution MRI and histopathology detected extramural venous invasion in rectal cancer. Ann Surg. 2015;261:473–9.
19. Battersby NJ, How P, Moran B, Stelzer S, West NP, Branagan G, et al. Prognostive validity of a low Rectal Cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model: the MERCURY II study. Ann Surg. 2016;263:751–60.
20. Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MHGM, de Lange-de Klerk ESM, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015;372:1324–32.
21. Nakajima Y, Yamada K, Imamura K, Kobayashi K. Radiologist supply and workload: international comparison—working Group of Japanese College of radiology. Radiat Med. 2008;26:455–65.
22. Smith NJ, Barbachano Y, Norman AR, Swift RI, Abulafi AM, Brown G. Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg. 2008;95:229–36.
23. Milone M, Manigrosso M, Velotti N, Torino S, Vozza A, Sarnelli G, et al. Completeness of total mesorectum excision of laparoscopic versus robotic surgery: a review with a meta-analysis. Int J Colorectal Dis. 2019;34:983–91.
24. Butterworth JW, Butterworth WA, Meyer J, Giacobino C, Buchs N, Ris F, et al. A systematic review and meta-analysis of robotic-assisted transabdominal total mesorectal excision and transanal total mesorectal excision: which approach offers optimal short-term outcomes for mid-to-low rectal adenocarcinoma? Tech Coloproctol. 2021;25:1183–98.

25. Hajibandeh S, Hajibandeh S, Eltair M, George AT, Thumbe V, Torrance AW, et al. Meta-analysis of transanal total mesorectal excision versus laparoscopic total mesorectal excision in management of rectal cancer. Int J Colorectal Dis. 2020;35:575–93.

26. Simillis C, Lal N, Thoukididou SN, Kontovounisios C, Smith JJ, Hompes R, et al. Open versus laparoscopic versus robotic versus Transanal Mesorectal excision for Rectal Cancer: a systematic review and network meta-analysis. Ann Surg. 2019;270:59–68.

27. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for Rectal Cancer: the ROLARR randomized clinical trial. JAMA. 2017;318:1569–80.

28. Roodbeen SX, Spinelli A, Bemelman WA, di Candido F, Cardepont M, Denost Q, et al. Local recurrence after Transanal Total Mesorectal excision for Rectal Cancer: a multicenter cohort study. Ann Surg. 2021;274:359–66.

How to cite this article: Takemasa I, Hamabe A, Ito M, Matoba S, Watanabe J, Hasegawa S, Japan Society of Laparoscopic Colorectal Surgery. Japanese multicenter prospective study investigating laparoscopic surgery for locally advanced rectal cancer with evaluation of CRM and TME quality (PRODUCT trial). Ann Gastroenterol Surg. 2022;6:767–777. https://doi.org/10.1002/ags3.12592